Travere Therapeutics Debt

TVTX Stock  USD 18.25  0.01  0.05%   
Travere Therapeutics holds a debt-to-equity ratio of 2.604. At this time, Travere Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year. Net Debt is likely to rise to about 363.9 M in 2024, whereas Short Term Debt is likely to drop slightly above 9.4 M in 2024. With a high degree of financial leverage come high-interest payments, which usually reduce Travere Therapeutics' Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

Travere Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Travere Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Travere Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Travere Therapeutics' stakeholders.
For most companies, including Travere Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Travere Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Travere Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
76.1026
Book Value
(0.39)
Operating Margin
(0.89)
Profit Margin
(1.73)
Return On Assets
(0.26)
At this time, Travere Therapeutics' Non Current Liabilities Total is fairly stable compared to the past year. Change To Liabilities is likely to rise to about 27.6 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 89.6 M in 2024.
  
Check out the analysis of Travere Therapeutics Fundamentals Over Time.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Travere Therapeutics Bond Ratings

Travere Therapeutics financial ratings play a critical role in determining how much Travere Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Travere Therapeutics' borrowing costs.
Piotroski F Score
4
PoorView
Beneish M Score
(3.30)
Unlikely ManipulatorView

Travere Therapeutics Debt to Cash Allocation

As Travere Therapeutics follows its natural business cycle, the capital allocation decisions will not magically go away. Travere Therapeutics' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Travere Therapeutics currently holds 404.78 M in liabilities with Debt to Equity (D/E) ratio of 2.6, implying the company greatly relies on financing operations through barrowing. Travere Therapeutics has a current ratio of 4.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Travere Therapeutics' use of debt, we should always consider it together with its cash and equity.

Travere Therapeutics Total Assets Over Time

Travere Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Travere Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Travere Therapeutics Debt Ratio

    
  46.0   
It appears slightly above 54% of Travere Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Travere Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Travere Therapeutics, which in turn will lower the firm's financial flexibility.

Travere Therapeutics Corporate Bonds Issued

Travere Short Long Term Debt Total

Short Long Term Debt Total

425.02 Million

At this time, Travere Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year.

Understaning Travere Therapeutics Use of Financial Leverage

Understanding the structure of Travere Therapeutics' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Travere Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last ReportedProjected for Next Year
Short and Long Term Debt Total404.8 M425 M
Net Debt346.6 M363.9 M
Short Term Debt9.8 M9.4 M
Long Term Debt377.3 M257.7 M
Short and Long Term Debt20.2 M18 M
Long Term Debt Total193.8 M172.3 M
Net Debt To EBITDA(1.06)(1.12)
Debt To Equity 1.90  2.00 
Interest Debt Per Share 5.30  5.56 
Debt To Assets 0.48  0.46 
Long Term Debt To Capitalization 0.65  1.20 
Total Debt To Capitalization 0.66  0.69 
Debt Equity Ratio 1.90  2.00 
Debt Ratio 0.48  0.46 
Cash Flow To Debt Ratio(0.73)(0.77)
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.